Stay updated on Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check36 days agoChange DetectedThe page has been updated to include the term 'Merkel Cell Carcinoma' and a new identifier for the study, while significant details about the study's design and inclusion/exclusion criteria have been removed.SummaryDifference31%
- Check44 days agoChange DetectedThe page has updated its version from v2.14.3 to v2.14.4 and removed a date of March 25, 2025, while adding a new date of December 31, 2024.SummaryDifference0.5%
- Check51 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check87 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check101 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference1%
Stay in the know with updates to Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial page.